This approval is big news in the cardiology community. We have been waiting for this for some time.
Preasugrel is an anti-platelet drug (like Plavix) and is vital when used after a stent placement to prevent stent thrombosis (clotting within the stent).
We have been excited about its approval ever since the publication of the TRITON-TIMI 38 trial.
That trial showed a 19% reduction in composite cardiovascular death, MI, and stroke compared with clopidogrel (9.9% versus 12.1%, P<0.001).
The number of patients who had a subsequent nonfatal MI dropped to 7.0% with prasugrel compared with 9.1% with clopidogrel.
However, there are some safety concerns as well. In that trial, major bleeding events occurred in 2.4% of prasugrel patients compared with 1.8% of those in the clopidogrel arm.
Most of the bleeing was in patients over 75 years of age, those frail and very thin and those with a history of a stroke.
Therefore, while the drug is not for everyone, it will give use another tool to help lower the risk of major cardiac events after stenting.
For news, education, and opinion on heart disease and nutrition for the everyday person -- follow me @ drportnay.blogspot.com